Medical Patent News

RSS

ARCA biopharma granted patent for methods of treating heart failure patients with bucindolol based on genetic testing

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing.

26 Mar 2010

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Genmab A/S announced today that on March 23, 2010 Genentech, Inc. and Biogen Idec, Inc. filed a declaratory relief complaint at the US District Court, Southern District of California against Genmab's collaboration partner GlaxoSmithKline (GSK) for patent infringement under US patent No 7,682,612 based on GSK's manufacture, marketing and sale of Arzerra™ in the United States for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL).

26 Mar 2010

ITC Judge rules in favor of Knowles Electronics on ADI’s microphone packages infringement issue

Knowles Electronics announced today that Judge Rogers of the International Trade Commission (ITC) issued his Initial Determination in which he found that Knowles was likely to succeed in showing that its patents cover Analog Devices, Inc. (ADI) MEMS microphone products.

26 Mar 2010

USPTO allows Pisgah Labs' patent application regarding imipramine pamoate

Pisgah Labs, a drug product development company and an active pharmaceutical ingredient manufacturer (API) located in western North Carolina, has received a patent allowance in a series of patent applications. The US Patent & Trademark Office (USPTO) has notified Pisgah Labs, Inc. that a patent application related to a therapeutically significant family of pharmaceutical polymorphic compositions of imipramine pamoate has been allowed. The patent application also includes methods of manufacturing, purifying and use in pharmaceutical preparations.

26 Mar 2010

U.S. Court vacates Greatbatch patent infringement verdict

The U.S. Court of Appeals for the Federal Circuit ruled in favor of Greatbatch by vacating an August 2008 patent infringement verdict regarding surgical introducers.

26 Mar 2010

PositiveID files patent application for iGlucose system

PositiveID Corporation announced today that it has filed with the U.S. Patent and Trademark Office a non-provisional patent application for its iGlucose system, currently under development, which uses wireless SMS messaging to automatically communicate a diabetic patient’s blood glucose levels from any data-capable glucose meter to an online database.

25 Mar 2010

US patent reinforces Ikonisys' position in digital image-analysis industry

Ikonisys, Inc., a leading provider of next-generation, cell-based diagnostic solutions, announced today that the United States Patent and Trademark Office has issued the company United States Patent No. 7,660,454 entitled “Process for identifying FISH signals.”

25 Mar 2010

Transcept Pharmaceuticals receives second patent for Intermezzo formulation

Transcept Pharmaceuticals, Inc. today announced that the second patent covering the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate, has been issued by the United States Patent and Trademark Office.

24 Mar 2010

Skinvisible obtains Korean patent for polymer delivery system

Skinvisible, Inc. announced today that the South Korean patent office has granted a patent for Invisicare®, the company's polymer delivery system for topical dermatology products.

24 Mar 2010

Pluristem Therapeutics receives European Patent on core 3D cell expansion technology

Pluristem Therapeutics Inc. today announced that it has been granted a European Patent on its core 3D cell expansion technology. The granting of the European patent follows the issuance of several corresponding US patents as well as corresponding patents in ten additional jurisdictions.

23 Mar 2010

Celladon Corporation receives USPTO notice of allowance covering MYDICAR for advanced heart failure

Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company's lead drug candidate MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.

23 Mar 2010

Texas jury returns binding verdict of invalidity on two Covidien's patent claims covering trocar seal technology

Applied Medical announced today that a United States District Court jury for the Eastern District of Texas returned a binding verdict of invalidity of two claims of a Covidien patent covering trocar seal technology.

23 Mar 2010

Uroplasty announces newly-issued patent for Urgent PC Neuromodulation System

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,668,598 covering the stimulation method used in the Urgent® PC Neuromodulation System.

23 Mar 2010

Covidien subsidiary wins patent infringement suit against Applied Medical Resources

Covidien, a leading global provider of healthcare products, today announced that a subsidiary of the Company won a patent infringement suit against Applied Medical Resources Corporation relating to certain of Applied Medical’s Kii™ and Universal® laparoscopic trocars.

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

Drug company fights for patent extension

The New York Times: The drug maker Medicines Company that makes the blood thinner called Angiomax, missed the application deadline to extend its patent back in 2000 by a day or two, depending on how you count.

20 Mar 2010

Providence receives U.S. patent for CPMMS

Providence today announces the receipt of a United States Patent for the Comprehensive Particulate Matter Measurement System (CPMMS) and the Methodology for its Use. Yousheng Zeng, PhD, PE, a principal of Providence, is the inventor of this system. Dr. Zeng explains, "Unlike current methods of monitoring air-borne particulate matter (PM), the CPMMS monitors the portion of PM that can reach and deposit in a human respiratory system."

19 Mar 2010

USPTO reissues composition of matter patent for Poniard Pharmaceuticals' picoplatin

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that the U.S. Patent & Trademark Office has granted and will reissue the composition of matter patent for picoplatin as RE41209, replacing USPN 5,665,771 ('771 patent), on April 6, 2010. The reissue was applied for May 8, 2009, and, on March 17, 2010, the USPTO released the "Issue Notification" for the reissue application.

19 Mar 2010

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.

18 Mar 2010

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

18 Mar 2010

Medical Patent News

ARCA biopharma granted patent for methods of treating heart failure patients with bucindolol based on genetic testing

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

ITC Judge rules in favor of Knowles Electronics on ADI’s microphone packages infringement issue

USPTO allows Pisgah Labs' patent application regarding imipramine pamoate

U.S. Court vacates Greatbatch patent infringement verdict

PositiveID files patent application for iGlucose system

US patent reinforces Ikonisys' position in digital image-analysis industry

Transcept Pharmaceuticals receives second patent for Intermezzo formulation

Skinvisible obtains Korean patent for polymer delivery system

Pluristem Therapeutics receives European Patent on core 3D cell expansion technology

Celladon Corporation receives USPTO notice of allowance covering MYDICAR for advanced heart failure

Texas jury returns binding verdict of invalidity on two Covidien's patent claims covering trocar seal technology

Uroplasty announces newly-issued patent for Urgent PC Neuromodulation System

Covidien subsidiary wins patent infringement suit against Applied Medical Resources

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Drug company fights for patent extension

Providence receives U.S. patent for CPMMS

USPTO reissues composition of matter patent for Poniard Pharmaceuticals' picoplatin

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News